Darbepoetin alfa: An effective treatment with flexible and simplified dosing for anemia in patients with cancer

Pharmacotherapy

Volumn 27, Issue 3, 2007, Pages 434-446

  Stevenson, James G ^a   Natale, James J ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anemia; Cancer; Chemotherapy; Darbepoetin alfa; MDS; Myelodysplastic syndrome

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS;

ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS;

EID: 33847306046     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.3.434     Document Type: Review

References (70)

1. Lawless G, Wilson-Royalty M, Meyers J. Epoetin alfa practice pattern usage in community practice sites [abstract]. Blood 2000;96:390b.
2. Ludwig H, Birgegard G, Barrett-Lee PJ, Krzakowski M. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European cancer anaemia survey (ECAS) [abstract]. Blood 2002;100:234a.
3. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-6.
4. Ludwig H, Pecorelli S. Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses. Semin Oncol 2000;27:18-19.
5. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-73.
6. Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology 2002;16:125-32.
7. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37:14-17.
8. Berndt E, Kallich J, Xu X, Haim Erder M, Lee H, Glaspy J. Reductions in anemia and fatigue are associated with improvements in productivity [abstract]. Blood 2002;100:876a.
9. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9.
10. Ortho Biotech Products L.P. Procrit (epoetin alfa) prescribing information. Bridgewater, NJ; 2005.
11. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotech 2003;21:414-21.
12. Amgen Inc. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA; 2005.
13. Amgen Inc. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA; 2006.
14. Moore K, Fortner B, Okon T. The impact of medical visits on patients with cancer and their caregivers [abstract]. In: Proceedings of the 28th annual congress of the Oncology Nursing Society, Denver, CO, May 1-4, 2003. Washington, DC: Oncology Nursing Society, 2003;abstract 73.
15. Tauer K, Zhu L, Former B. The impact of anemia treatment visits on the patient and their caregiver [abstract]. Proc Am Soc Clin Oncol 2004;23:753.
16. Meehan KR, Tchekmedyian NS, Smith RE, Kleinman L, Fitzmaurice T, Kallich JD. An activity-based costing estimate of anemia correction activities in an oncology practice [abstract]. Blood 2002;100:502b.
17. Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003;23(12 pt 2):101S-9.
18. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002;16:17-24.
19. Johnston E, Crawford J. The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds. Principles and practices of supportive oncology. Philadelphia, PA: Lippincott-Raven, 1998:549-69.
20. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-11.
21. Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000;64:353-8.
22. Nowrousian MR, Kasper C, Oberhoff C, et al. Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer B, eds. rhErythropoietin in cancer supportive treatment. New York: Marcel Dekker, 1996:13-34.
23. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-9.
24. Komrokji R, Bennett JM. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep 2003;2:179-85.
25. Albitar M, Zhou W, Giles F. Myelodysplastic syndrome: from morphology to biology. Curr Hematol Rep 2004;3:159-64.
26. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood 2002;100:2303-20.
27. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16.
28. National Comprehensive Cancer Network Inc. NCCN practice guidelines in oncology. Cancer and treatment-related anemia, version 1, January 23, 2006. Available from http://www.nccn.org. Accessed February 28, 2006.
29. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76.
30. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
31. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-8.
32. Vadhan-Raj S, Mirtsching B, Gregory SA, et al. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA) [abstract]. Proc Am Soc Clin Oncol 2004;23:740.
33. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit study group. J Clin Oncol 1997;15:1218-34.
34. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol 1998;16:3412-25.
35. Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
36. Thames WA, Smith SL, Schiefele AC, Yao B, Giffin SA, Alley JL. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 vg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24:313-23.
37. Schwartzberg L, Shiftman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study to compare the utilization patterns and clinical outcomes of erythropoietic proteins for chemotherapy-induced anemia. Clin Ther 2003;25:2781-96.
38. Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005;62:54-62.
39. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-8.
40. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
41. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50.
42. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 study group trial. J Clin Oncol 2006;24:2290-7.
43. Seidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment Comparative effectiveness review no. 3 (prepared by Blue Cross and Blue Shield Association technology evaluation center evidence-based practice center under contract no. 290-02-0026). Rockville, MD: Agency for Healthcare Research and Quality May 2006. Available from www.effectivehealthcare.ahrq.gov/ reports/final. cfm. Accessed May 31, 2006.
44. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
45. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9.
46. Rearden T, Charu V, Saidman B, et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (C1A) [abstract]. Proc Am Soc Clin Oncol 2004;23:741.
47. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every 3 weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-17.
48. Canon J-L, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98;273-84.
49. Taylor K, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia [abstract]. Blood 2005;106:abstract 3556.
50. Silberstein P, Boccia R, Liu D, et al. Synchronicity: evaluating darbepoetin alfa administered at 300 pg every three weeks to treat chemotherapy-induced anemia in breast cancer patients. Presented at the 28th annual San Antonio breast cancer symposium, San Antonio, TX, December 8-11, 2005.
51. Canon J-L, Vansteenkiste J, Bodoky G, et al. Effect of dose reductions on response to 500-pg darbepoetin alfa administered once every 3 weeks for the treatment of chemotherapy-induced anemia: analysis from a randomized, double-blind, active-controlled trial [abstract]. Blood 2005;106:abstract 3558.
52. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006;106:223-33.
53. Smith RE, Tchekmedyian NS, Chan D, et al. A dose-finding and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-88.
54. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJJ, ed. Blood cell growth factors: their present and future use in hematology and oncology; proceedings of the Beijing symposium. Dayton, OH: AlphaMed Press, 1991:121-41.
55. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-34.
56. Charu V, Belani CP, Gill AN, et al. A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer [abstract]. Proc Am Soc Clin Oncol 2004;23:741.
57. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4.
58. Gotlib J, Quesada S, Bhamidipati J, et al. Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS): preliminary efficacy, safety, and in vitro results [abstract]. Blood 2004;104:abstract 4737.
59. Oliva EN, Ronco F, Danova M, et al. Darbepoetin efficacy in myelodysplastic syndrome [abstract]. Blood 2004;104:abstract 4704.
60. Mannone L, Gardin C, Quarre MC, et al. High response rate to darbepoetin alfa in "low risk" MDS: results of a phase II study [abstract]. Blood 2004;104:abstract 69.
61. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9.
62. Patton J, Mun Y, Wallace J. Darbepoetin alfa maintains hemoglobin levels in patients with myelodysplastic syndromes (MDS) after therapeutic interchange from epoetin alfa: results of a retrospective chart review [abstract]. Blood 2004;104:abstract 4708.
63. Gabrilove J, Paquette R, Lyons R, et al. A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome [abstract]. Blood 2005;106:abstract 2541.
64. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
65. Bennett JM, Catovsky D, Daniel MT, et al, for the French-American-British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
66. Hedenus M, Canon J-L, Kotasek D, et al. Effects of dose adjustment rules on safety during erythropoietic therapy: a retrospective analysis of darbepoetin alfa administered either every 3 weeks or weekly [abstract]. Blood 2005;106:abstract 3376.
67. Leyland-Jones B, Semiglasov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
68. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
69. Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration. Oncologic drugs advisory committee, May 4, 2004 meeting transcript. Available from http://www.fda.gov/ ohrms/dockets/ac/cder04.html#Oncologic. Accessed September 30, 2005.
70. Freemantle N, Yao B, Calvert M, Lillie T. Impact of darbepoetin alfa on transfusion, hemoglobin response, and survival in cancer patients with chemotherapy-induced anemia: results of a meta-analysis of randomized, placebo-controlled trials [abstract]. Blood 2005;106:abstract 3116.